Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.
The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.
The premier platform not only for the presentation of new science, but also for unique networking opportunities.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.
In recent years, deaths from non-small cell lung cancer (NSCLC) have decreased even faster than the decrease in NSCLC incidence.
These are the latest cancer treatments approved by the FDA.
Data from a large COVID-19 and cancer registry also showed that hydroxychloroquine plus azithromycin is associated with higher mortality.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.